Teriparatide biosimilar (Dongguan Baolijian Bioengineering)

The pharmacokinetic characteristics of recombinant human parathyroid hormone (1-34) after single subcutaneous injection of low, medium and high doses were observed in 12 healthy subjects (half male and half female), as well as the linear relationship between plasma drug AUC and the administered dose. The pharmacokinetic characteristics of recombinant human parathyroid hormone (1-34) after multiple subcutaneous injections were observed in 12 subjects (half male and half female), as well as the cumulative index of plasma drug AUC at steady state.

To further verify the safety and efficacy of recombinant human parathyroid hormone (1-34) for injection in the treatment of osteoporosis in postmenopausal women.